Renaissance Technologies LLC Makes New $1.42 Million Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Renaissance Technologies LLC bought a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 129,043 shares of the company's stock, valued at approximately $1,423,000. Renaissance Technologies LLC owned about 0.24% of Stoke Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of STOK. KLP Kapitalforvaltning AS bought a new position in shares of Stoke Therapeutics during the 4th quarter worth about $63,000. Teacher Retirement System of Texas bought a new position in Stoke Therapeutics during the fourth quarter valued at about $113,000. China Universal Asset Management Co. Ltd. bought a new position in Stoke Therapeutics during the fourth quarter valued at about $124,000. Invesco Ltd. acquired a new position in Stoke Therapeutics in the 4th quarter valued at approximately $133,000. Finally, Wells Fargo & Company MN lifted its position in shares of Stoke Therapeutics by 51.2% in the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock worth $185,000 after acquiring an additional 5,682 shares during the period.

Stoke Therapeutics Trading Down 2.4 %

Shares of Stoke Therapeutics stock traded down $0.24 during midday trading on Friday, reaching $9.63. The company had a trading volume of 640,908 shares, compared to its average volume of 710,291. The stock has a fifty day simple moving average of $7.90 and a 200 day simple moving average of $10.18. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58. The company has a market capitalization of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on STOK shares. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $24.67.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,532 shares of company stock worth $143,332. Company insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.